Genetic analysis of praziquantel response in schistosome parasites implicates a transient receptor potential channel.

ABSTRACT: Mass drug administration with praziquantel (PZQ) monotherapy is considered the mainstay for control and elimination of the parasites causing schistosomiasis in humans. This drug shows imperfect cure rates in the field, and parasites showing reduced PZQ response can be selected in the laboratory, but the extent of resistance in Schistosoma mansoni populations is unknown. We examined the genetic basis of the variation in response in a PZQ-selected S. mansoni population (SmLE-PZQ-R) in which 35% of the parasitic worms survive high-dose PZQ (73 micrograms per milliliter) treatment. We used genome-wide association to map loci underlying PZQ response and identified a transient receptor potential (Sm.TRPM_PZQ) channel (Smp_246790) within the major chromosome 3 peak

SUBMITTER: Le Clec'h W 

PROVIDER: S-EPMC9491494 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature